Grace Therapeutics, Inc. (APO.CA) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Grace Therapeutics, Inc. (NASDAQ:GRCE) is a clinical-stage biotechnology company focused on developing pharmaceutical treatments for rare and orphan diseases. Originally incorporated in 2002 as Acasti Pharma Inc., the company underwent a strategic transformation and rebranded to Grace Therapeutics in October 2024. Headquartered in Princeton, New Jersey, the company went public in February 2012 and has since pivoted from its original focus to concentrate on addressing unmet medical needs in rare disease populations where treatment options are limited or non-existent.

Ask drillr about Grace Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−21.45M

Op. CF (TTM)

−10.30M

Latest newsMore news →

Grace Therapeutics announced its financial results for the first quarter of fiscal 2027 (three months ended June 30, 2026).38d ago

Grace Therapeutics announced a $10 million private placement, with expected gross proceeds anticipated to extend the company's cash runway to the end of calendar 2028.47d ago

Latest newsMore news →

Grace Therapeutics announced its financial results for the first quarter of fiscal 2027 (three months ended June 30, 2026).38d ago Grace Therapeutics announced a $10 million private placement, with expected gross proceeds anticipated to extend the company's cash runway to the end of calendar 2028.47d ago Grace Therapeutics received Type A meeting minutes from the U.S. Food and Drug Administration regarding a Complete Response Letter for GTx-104.54d ago